Abstract
Rapidly developing pulmonary fibrosis associated with the use of the anti-cancer drug oxaliplatin has been reported mainly by Asiatic literature as isolate case reports. This rare but potentially fatal side effect has neither identified risk factors nor established treatment guideline. We report here a new clinical case concerning a patient with advanced gastric cancer treated with the oxaliplatin-based FOLFOX regimen along with a review of the literature as well as a discussion of emerging experimental treatment mainly based on imatinib.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Benzamides
-
Fluorouracil / administration & dosage
-
Fluorouracil / adverse effects
-
Fluorouracil / therapeutic use
-
Humans
-
Imatinib Mesylate
-
Leucovorin / administration & dosage
-
Leucovorin / adverse effects
-
Leucovorin / therapeutic use
-
Male
-
Middle Aged
-
Organoplatinum Compounds / administration & dosage
-
Organoplatinum Compounds / adverse effects*
-
Organoplatinum Compounds / therapeutic use
-
Oxaliplatin
-
Piperazines / therapeutic use
-
Protein Kinase Inhibitors / therapeutic use
-
Pulmonary Fibrosis / chemically induced*
-
Pulmonary Fibrosis / drug therapy
-
Pulmonary Fibrosis / pathology
-
Pyrimidines / therapeutic use
-
Stomach Neoplasms / drug therapy
-
Stomach Neoplasms / pathology
Substances
-
Benzamides
-
Organoplatinum Compounds
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Oxaliplatin
-
Imatinib Mesylate
-
Leucovorin
-
Fluorouracil